ACAlexander A. Chumanevich

Alexander A. Chumanevich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander A. Chumanevich has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Anastasiya A. Chumanevich

    Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA

    1 shared publication
  • Balazs Gyorffy

    Department of Bioinformatics, Semmelweis University, Budapest, Hungary

    1 shared publication
  • Bryson Massey

    Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA

    1 shared publication
  • Campbell McInnes

    Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter Street, Columbia, South Carolina 29208, United States

    1 shared publication
  • Carolyn E. Banister

    Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA

    1 shared publication
  • Chang-Uk Lim

    Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA

    1 shared publication

Latest Publications

  • Open Access

    Mediator kinase inhibition reverses castration resistance of advanced prostate cancer

    by Jing Li, Thomas A. Hilimire, Yueying Liu, Lili Wang, Jiaxin Liang, Balazs Gyorffy, Vitali Sikirzhytski, Hao Ji, Li Zhang, Chen Cheng, et al.

    Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling, but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition of CDK8 and CDK19 reverses the castration-resistant phenotype and restores the sensitivity of CRPC xenografts to androgen deprivation in vivo. Prolonged CDK8/19 inhibitor treatment combined with castration not only suppressed the growth of CRPC xenografts but also induced tumor regression and cures. Transcriptomic analysis revealed that Mediator kinase inhibition amplified and modulated the effects of castration on gene expression, disrupting CRPC adaptation to androgen deprivation. Mediator kinase inactivation in tumor cells also affected stromal gene expression, indicating that Mediator kinase activity in CRPC molded the tumor microenvironment. The combination of castration and Mediator kinase inhibition downregulated the MYC pathway, and Mediator kinase inhibition suppressed a MYC-driven CRPC tumor model even without castration. CDK8/19 inhibitors showed efficacy in patient-derived xenograft models of CRPC, and a gene signature of Mediator kinase activity correlated with tumor progression and overall survival in clinical samples of metastatic CRPC. These results indicate that Mediator kinases mediated androgen-independent in vivo growth of CRPC, supporting the development of CDK8/19 inhibitors for the treatment of this presently incurable disease.


  • Open Access

    The synthetic food dye, Red 40, causes DNA damage, causes colonic inflammation, and impacts the microbiome in mice

    by Qi Zhang, Alexander A. Chumanevich, Ivy Nguyen, Anastasiya A. Chumanevich, Nora Sartawi, Jake Hogan, Minou Khazan, Quinn Harris, Bryson Massey, Ioulia Chatzistamou, et al.